menu
    • menu
    [{"orgOrder":0,"company":"Boryung Pharmaceutical Co., Ltd","sponsor":"PharmaMar","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Plitidepsin","moa":"Elongation factor 1-alpha 2","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Boryung Pharmaceutical Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Boryung Pharmaceutical Co., Ltd \/ PharmaMar","highestDevelopmentStatusID":"6","companyTruncated":"Boryung Pharmaceutical Co., Ltd \/ PharmaMar"},{"orgOrder":0,"company":"Institut Bergoni\u00e9","sponsor":"Ministry of Health, France | PharmaMar","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Plitidepsin","moa":"Elongation factor 1-alpha 2","graph1":"Oncology","graph2":"Phase II","graph3":"Institut Bergoni\u00e9","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Institut Bergoni\u00e9 \/ Ministry of Health, France | PharmaMar","highestDevelopmentStatusID":"8","companyTruncated":"Institut Bergoni\u00e9 \/ Ministry of Health, France | PharmaMar"},{"orgOrder":0,"company":"Fundaci\u00f3n FLS","sponsor":"PharmaMar | IrsiCaixa","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SPAIN","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Plitidepsin","moa":"Elongation factor 1-alpha 2","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Fundaci\u00f3n FLS","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Fundaci\u00f3n FLS \/ PharmaMar | IrsiCaixa","highestDevelopmentStatusID":"8","companyTruncated":"Fundaci\u00f3n FLS \/ PharmaMar | IrsiCaixa"},{"orgOrder":0,"company":"PharmaMar","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SPAIN","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Plitidepsin","moa":"Elongation factor 1-alpha 2","graph1":"Oncology","graph2":"Phase III","graph3":"PharmaMar","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"PharmaMar \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"PharmaMar \/ Undisclosed"},{"orgOrder":0,"company":"PharmaMar","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SPAIN","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Plitidepsin","moa":"Elongation factor 1-alpha 2","graph1":"Oncology","graph2":"Phase III","graph3":"PharmaMar","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"PharmaMar \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"PharmaMar \/ Undisclosed"},{"orgOrder":0,"company":"PharmaMar","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SPAIN","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Plitidepsin","moa":"Elongation factor 1-alpha 2","graph1":"Oncology","graph2":"Phase III","graph3":"PharmaMar","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"PharmaMar \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"PharmaMar \/ Undisclosed"},{"orgOrder":0,"company":"PharmaMar","sponsor":"Apices Soluciones","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SPAIN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Plitidepsin","moa":"Elongation factor 1-alpha 2","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"PharmaMar","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"PharmaMar \/ Apices Soluciones","highestDevelopmentStatusID":"10","companyTruncated":"PharmaMar \/ Apices Soluciones"},{"orgOrder":0,"company":"PharmaMar","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SPAIN","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Plitidepsin","moa":"Elongation factor 1-alpha 2","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"PharmaMar","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"PharmaMar \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"PharmaMar \/ Undisclosed"},{"orgOrder":0,"company":"PharmaMar","sponsor":"Apices Soluciones","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SPAIN","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Plitidepsin","moa":"Elongation factor 1-alpha 2","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"PharmaMar","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"PharmaMar \/ Apices Soluciones","highestDevelopmentStatusID":"10","companyTruncated":"PharmaMar \/ Apices Soluciones"},{"orgOrder":0,"company":"PharmaMar","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SPAIN","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Plitidepsin","moa":"Elongation factor 1-alpha 2","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"PharmaMar","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"PharmaMar \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"PharmaMar \/ Undisclosed"},{"orgOrder":0,"company":"PharmaMar","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SPAIN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Plitidepsin","moa":"Elongation factor 1-alpha 2","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"PharmaMar","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"PharmaMar \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"PharmaMar \/ Undisclosed"},{"orgOrder":0,"company":"PharmaMar","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SPAIN","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Plitidepsin","moa":"Elongation factor 1-alpha 2","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"PharmaMar","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"PharmaMar \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"PharmaMar \/ Undisclosed"},{"orgOrder":0,"company":"PharmaMar","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SPAIN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Plitidepsin","moa":"Elongation factor 1-alpha 2","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"PharmaMar","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"PharmaMar \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"PharmaMar \/ Undisclosed"},{"orgOrder":0,"company":"PharmaMar","sponsor":"Apices Soluciones","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SPAIN","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Plitidepsin","moa":"Elongation factor 1-alpha 2","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"PharmaMar","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"PharmaMar \/ Apices Soluciones","highestDevelopmentStatusID":"10","companyTruncated":"PharmaMar \/ Apices Soluciones"},{"orgOrder":0,"company":"PharmaMar","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SPAIN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Plitidepsin","moa":"Elongation factor 1-alpha 2","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"PharmaMar","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"PharmaMar \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"PharmaMar \/ Undisclosed"},{"orgOrder":0,"company":"PharmaMar","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SPAIN","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Plitidepsin","moa":"Elongation factor 1-alpha 2","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"PharmaMar","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"PharmaMar \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"PharmaMar \/ Undisclosed"},{"orgOrder":0,"company":"PharmaMar","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SPAIN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Plitidepsin","moa":"Elongation factor 1-alpha 2","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"PharmaMar","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"PharmaMar \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"PharmaMar \/ Undisclosed"},{"orgOrder":0,"company":"PharmaMar","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SPAIN","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Plitidepsin","moa":"Elongation factor 1-alpha 2","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"PharmaMar","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"PharmaMar \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"PharmaMar \/ Undisclosed"},{"orgOrder":0,"company":"PharmaMar","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SPAIN","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Plitidepsin","moa":"Elongation factor 1-alpha 2","graph1":"Oncology","graph2":"Phase II","graph3":"PharmaMar","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection, Powder, Lyophilized","sponsorNew":"PharmaMar \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"PharmaMar \/ Undisclosed"},{"orgOrder":0,"company":"PharmaMar","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SPAIN","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Plitidepsin","moa":"Elongation factor 1-alpha 2","graph1":"Oncology","graph2":"Phase II","graph3":"PharmaMar","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PharmaMar \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"PharmaMar \/ Undisclosed"},{"orgOrder":0,"company":"UCSF QBI","sponsor":"Icahn School of Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Plitidepsin","moa":"Elongation factor 1-alpha 2","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"UCSF QBI","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"UCSF QBI \/ Icahn School of Medicine","highestDevelopmentStatusID":"4","companyTruncated":"UCSF QBI \/ Icahn School of Medicine"}]

    Find Clinical Drug Pipeline Developments & Deals for Plitidepsin

    Menu

    Plitidepsin

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Fundación FLS

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Fundación FLS

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Plitidepsin

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : PharmaMar | IrsiCaixa

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study to Evaluate the Efficacy and Safety of Plitidepsin in Adults with Post-COVID-19 Condition (PCC)

                            Details : Plitidepsin is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Post-Acute COVID-19 Syndrome.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            January 09, 2025

                            Lead Product(s) : Plitidepsin

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : PharmaMar | IrsiCaixa

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            PharmaMar

                            Spain arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            PharmaMar

                            Spain arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Plitidepsin

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Plitidepsin Versus Control in Immunocompromised Adult Participants With Symptomatic COVID-19 Requiring Hospita...

                            Details : Plitidepsin is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of COVID-19.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            January 30, 2023

                            Lead Product(s) : Plitidepsin

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            PharmaMar

                            Spain arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            PharmaMar

                            Spain arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Plitidepsin

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Life Science Alliance Journal Publishes Results of Plitidepsin in Patients With Covid-19, Which Includes Addit...

                            Details : The final results of APLICOV-PC study (Phase I-II), demonstrate the safety of Aplidin (plitidepsin) use in patients with COVID-19 and postulate a positive therapeutic impact on the evolution of the disease.

                            Product Name : Aplidin

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            January 11, 2022

                            Lead Product(s) : Plitidepsin

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            PharmaMar

                            Spain arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            PharmaMar

                            Spain arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Plitidepsin

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I/ Phase II

                            Sponsor : Apices Soluciones

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Extension Study in a Cohort of Adult Patients With COVID-19 Infection

                            Details : Plitidepsin is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of COVID-19.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            November 16, 2021

                            Lead Product(s) : Plitidepsin

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Apices Soluciones

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            PharmaMar

                            Spain arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            PharmaMar

                            Spain arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Plitidepsin

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Spain's PharmaMar Says Covid-19 Treatment Drug Shows Clinical Efficacy in Trials

                            Details : The APLICOV-PC study evaluated three cohorts of hospitalized patients with mild, moderate or severe disease, with three different dose levels of plitidepsin (1.5mg - 2.0mg - 2.5mg), administered on three consecutive days.

                            Product Name : Aplidin

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            May 26, 2021

                            Lead Product(s) : Plitidepsin

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            PharmaMar

                            Spain arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            PharmaMar

                            Spain arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Plitidepsin

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Trial to Determine the Efficacy/Safety of Plitidepsin vs Control in Patients With Moderate COVID-19 Infection

                            Details : Plitidepsin is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of COVID-19.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            March 05, 2021

                            Lead Product(s) : Plitidepsin

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            PharmaMar

                            Spain arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            PharmaMar

                            Spain arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Plitidepsin

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            UK Approves the Start of the Phase III NEPTUNO Trial with PharmaMar's Aplidin® (Plitidepsin) for the Treatmen...

                            Details : Pharma Mar has obtained MHRA approval for UK patients to participate in the Phase III NEPTUNO clinical trial, which will determine the efficacy of Aplidin® for the treatment of hospitalized patients with moderate COVID-19 infection.

                            Product Name : Aplidin

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            February 17, 2021

                            Lead Product(s) : Plitidepsin

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            PharmaMar

                            Spain arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            PharmaMar

                            Spain arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Plitidepsin

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Sponsor : Apices Soluciones

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            The Peer Review journal Science Confirms the Potent Activity of PharmaMar's Plitidepsin Against SARS-CoV-2

                            Details : PharmaMar’s cancer drug Aplidin (plitidepsin) has demonstrated ‘potent preclinical efficacy’ against SARS-CoV-2, the virus which causes COVID-19. Aplidin inhibits the eEF1A protein, which is associated with the SARS-CoV-2 virus.

                            Product Name : Aplidin

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            January 26, 2021

                            Lead Product(s) : Plitidepsin

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Sponsor : Apices Soluciones

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            UCSF QBI

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            UCSF QBI

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Plitidepsin

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Preclinical

                            Sponsor : Icahn School of Medicine

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            UCSF QBI and Icahn School of Medicine at Mount Sinai Scientists Report New Preclinical Data on Plitidepsin for...

                            Details : Plitidepsin shows potent anti-viral effect in preclinical models of original SARS-CoV-2 as well as the new mutant U.K. strain, and by inhibiting a key host protein, has the potential to have antiviral activity against other future mutations and viruses.

                            Product Name : Aplidin

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            January 25, 2021

                            Lead Product(s) : Plitidepsin

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Preclinical

                            Sponsor : Icahn School of Medicine

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            PharmaMar

                            Spain arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            PharmaMar

                            Spain arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Plitidepsin

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            PharmaMar Plans Phase III Trial of Cancer Drug for COVID-19, Shares Jump

                            Details : There was a substantial reduction in viral load and the C-reactive protein (CRP) in patients, and that 80.7% of patients had been discharged before the 15th day of hospitalisation, and 38.2% before the eighth day.

                            Product Name : Aplidin

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            October 16, 2020

                            Lead Product(s) : Plitidepsin

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth